TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate cancer treatment decisions.
The MarketWatch News Department was not involved in the creation of this content. EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation ...
4don MSN
Joe Biden's Prostate Cancer Went Undetected Before Spreading — Doctors Explain How It Could Happen
Doctors followed standard testing guidelines, which recommend discontinuing screenings for men over 70 years old. Should that ...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...
A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...
The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through ...
The MarketWatch News Department was not involved in the creation of this content. EDMONTON, AB, April 20, 2026 /CNW/ - Nanostics Inc., a precision health company advancing diagnostic innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results